Mycobacterium Tuberculosis Infections In Solid Organ Transplantation
Publication Date: March 1, 2019
Last Updated: March 14, 2022
Recommendations
All transplant candidates should undergo screening for TB with careful epidemiologic history, exam, TST or IGRA testing, and CXR or Chest CT. (Moderate, Strong)
317067
Transplant candidates with positive TST or IGRA should be considered for latent TB therapy once active TB is ruled out. (Moderate, Strong)
317067
IGRA may have advantages over TST in transplant, especially in those who received prior BCG vaccine, or have end‐stage renal disease or advanced liver disease. (Low, Strong)
317067
Those with high epidemiologic risk (including close or prolonged contact with a case of active TB) and/or chest radiographic evidence of prior TB without adequate treatment should be considered for latent TB therapy even with an indeterminate or negative TST or IGRA test. (Low, Strong)
317067
Those who have received an organ from a donor who is TST‐positive, had recent exposure to active TB, or had radiographic evidence of untreated TB should be considered for latent TB therapy. (Low, Strong)
317067
All living donors should undergo screening for TB and should be evaluated for a need for therapy. (Low, Strong)
317067
Active TB in the donor is a contraindication to organ donation, and active TB in a transplant candidate needs to be treated prior to transplant. (Moderate, Strong)
317067
TREATMENT OF ACTIVE TB
First‐line therapy for transplant patients with active TB disease is the same as for immunocompetent and other hosts. (High, Strong)
317067
Daily dosing of active TB therapy is recommended as opposed to twice‐ or thrice‐weekly dosing. (Moderate, Strong)
317067
Treatment duration for uncomplicated pulmonary TB is at least 6 months, but longer for cavitary disease or disease with persistent sputum culture‐positive status after 2 months of therapy. (High, Strong)
317067
- for bone and joint disease (6‐9 months)
(High, Strong)317067
- for central nervous system disease (9‐12 months)
(, )317067
- severe disseminated disease (6‐9 months)
(Moderate, Strong)317067
Directly observed therapy (DOT) programs are recommended for transplant recipients. (Moderate, Strong)
317067
Title
Mycobacterium Tuberculosis Infections In Solid Organ Transplantation
Authoring Organization
American Society of Transplantation
Publication Month/Year
March 1, 2019
Last Updated Month/Year
January 29, 2024
External Publication Status
Published
Country of Publication
US
Document Objectives
These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of tuberculosis in the pre‐ and post‐transplant period.
Target Patient Population
Pre-/post-transplant recipient
Inclusion Criteria
Female, Male, Adolescent, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Operating and recovery room, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Diagnosis, Prevention, Management
Diseases/Conditions (MeSH)
D014180 - Transplantation, D019737 - Transplants, D009161 - Mycobacterium, D009164 - Mycobacterium Infections, D009169 - Mycobacterium tuberculosis
Keywords
Mycobacterium tuberculosis, transplant
Source Citation
Subramanian, AK, Theodoropoulos, NM; on behalf of the Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019; 33:e13513.